Verification of therapeutic application of maxillary/mandibular bone marrow-derived stem cells for medication-related osteonecrosis of the jaw

2022 Fiscal Year Final Research Report

• Project/Area Number: 21K17024
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 57040:Regenerative dentistry and dental engineering-related
• Research Institution: Kagoshima University
• Principal Investigator: MATSUMOTO Akihiko 鹿児島大学, 医歯学総合研究科, 客員研究員 (60849107)
• Project Period (FY): 2021-04-01 – 2023-03-31
• Keywords: 薬剤関連顎骨壊死 / 間葉系幹細胞

Outline of Final Research Achievements

The onset of medication related osteonecrosis of the jaw (MRONJ) is known as a complication of administration of BP preparations, but no treatment has been established. MRONJ is also caused by tooth extractions and denture ulcers, and interferes with surgical pretreatment of prostheses, making ideal prosthesis treatment difficult. Recently, regenerative medicine using pluripotent mesenchymal stem cells (MSCs) has attracted attention. Maxillary/mandibular bone marrow derived MSCs (MBMSCs) are thought to be useful in regenerative medicine in the dental,and are expected to be applied as a treatment for MRONJ.
In this study, we attempted to establish the MRONJ model using mice and rats. Furthermore, we evaluated the therapeutic effect of MBMSCs transplantation into the extraction socket of MRONJ model rats.

Free Research Field

歯科補綴学

Academic Significance and Societal Importance of the Research Achievements

MRONJの発症機序は未だ不明な点が多く治療法も確立されていない。治療法については保存的治療を第一選択とし、保存的治療で経過観察を行う間、口腔内に長期間骨が露出した状態が続き、義歯などの補綴装置は装着困難となり、咀嚼機能の著しい低下を招く。このため、MRONJに対する新たな治療法の開発が強く求められている。
本研究はMRONJに対する新たな治療法開発を目的とした研究であり、MRONJモデルに対してMBMSC移植による治療効果を評価した初めての研究である。従って、この研究成果はMRONJに対するMBMSC移植治療法開発のための基礎となる研究であり、学術的・社会的意義の高いものである。